Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) ...

The phase 2 trial of CT-388, a once-weekly subcutaneous injection acquired as part of its $2.7 billion takeover of Carmot ...

The UK has lost its measles elimination status, according to the World Health Organization (WHO), after recording 2,911 ...

In this second of three articles on The Sunday Times top 100 tech companies list, pharmaphorum is focusing on the first nine ...

At the JP Morgan Healthcare conference this year, a lot of the discourse around AI drug discovery focused on making the leap ...

In the evolving landscape of healthcare professional (HCP) engagement, face-to-face interactions remain a cornerstone. They ...

A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan ...

A new technology elucidated yesterday in the journal Nature has the potential to be a leap forward in DNA synthesis, allowing ...

NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...

In this interview conducted during JPM Week in San Francisco, pharmaphorum editor-in-chief Jonah Comstock spoke with Adrian ...

That is according to the Wall Street Journal, which has said MSD failed to reach an agreement with Revolution on a fair price for the business, which has a cancer-focused pipeline headed by ...

The Bio-Hermes-002 study, involving 1,000 volunteers aged over 60 in the UK, US and Canada, is using finger-prick testing to ...